Infant Bacterial Therapeutics ABIFTBF 29 Forward Dividend Yield % is 0.00% as of Jun. 28, 2026. GuruFocus rates IFTBF with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 145 Biotechnology companies, Infant Bacterial Therapeutics AB ranks worse than 689654.48% on this metric.
IFTBF's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.57 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Infant Bacterial Therapeutics AB (OTCPK:IFTBF) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Infant Bacterial Therapeutics AB Forward Dividend Yield % Related Terms
IFTBF vs VRTX, REGN, ALNY: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Infant Bacterial Therapeutics AB Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Infant Bacterial Therapeutics AB's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Infant Bacterial Therapeutics AB (IFTBF) has a Forward Dividend Yield % of 0.00% as of Jun. 28, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Infant Bacterial Therapeutics AB and its competitors. According to the industry distribution chart, Infant Bacterial Therapeutics AB ranks #999999 out of 145 companies in the Biotechnology industry.
Is Infant Bacterial Therapeutics AB's Forward Dividend Yield % too high?
Infant Bacterial Therapeutics AB's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Infant Bacterial Therapeutics AB ranks #999999 out of 145 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Infant Bacterial Therapeutics AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Infant Bacterial Therapeutics AB's Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Infant Bacterial Therapeutics AB ranks #999999 out of 145 companies for Forward Dividend Yield %. This places Infant Bacterial Therapeutics AB in the lower half of its industry. The industry median Forward Dividend Yield % is 1.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.57, based on 145 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Infant Bacterial Therapeutics AB and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Infant Bacterial Therapeutics AB's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infant Bacterial Therapeutics AB stock overvalued right now?
Infant Bacterial Therapeutics AB (IFTBF) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Infant Bacterial Therapeutics AB's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Infant Bacterial Therapeutics AB (IFTBF), the current Forward Dividend Yield % is 0.00% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Infant Bacterial Therapeutics AB Business Description
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance, Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118, and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
29GF Score
Get the complete analysis for IFTBF
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IFTBF has been successfully added to your 